Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study
about
Dose schedule optimization and the pharmacokinetic driver of neutropeniaDo difficulties in swallowing medication impede the use of hydroxyurea in children?Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.Formulations for children: problems and solutionsA Pilot Study of Circulating Endothelial and Hematopoietic Progenitor Cells in Children With Sarcomas.A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.The potential of sunitinib as a therapy in ovarian cancer.Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Bone sarcomas: from biology to targeted therapies.
P2860
Q28544635-E2316F14-9729-423C-B3FA-D61F937FDF5BQ34285113-B2D7685D-B0F4-4D41-A9D3-F9D85AB00B04Q34543413-8498D1D8-6DBE-4E62-BCE0-35C092795D18Q35135943-A11D229E-5E85-472D-BE34-7B407FFE0862Q35862618-1E3566C9-F5FD-4BB9-A6FB-B477480AF996Q36888962-6375D1B3-4717-465D-9A8C-7FD3D5BCBECEQ37094908-FFFC1F9A-12BE-4B33-9516-8F3263BC5EA7Q38144166-58A3EAF7-E5CF-4CE7-9C48-88B85C9E2397Q38627885-9570626C-E498-45C3-B846-11DAFB81AF54Q38961012-20C4040B-3A6E-4874-BB50-28DC4EE111E6Q41923624-472A5FCD-9BDC-43D8-A20C-72AF3B284398
P2860
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Tolerability and pharmacokinet ...... hildren's Oncology Group study
@ast
Tolerability and pharmacokinet ...... hildren's Oncology Group study
@en
Tolerability and pharmacokinet ...... ildren's Oncology Group study.
@nl
type
label
Tolerability and pharmacokinet ...... hildren's Oncology Group study
@ast
Tolerability and pharmacokinet ...... hildren's Oncology Group study
@en
Tolerability and pharmacokinet ...... ildren's Oncology Group study.
@nl
prefLabel
Tolerability and pharmacokinet ...... hildren's Oncology Group study
@ast
Tolerability and pharmacokinet ...... hildren's Oncology Group study
@en
Tolerability and pharmacokinet ...... ildren's Oncology Group study.
@nl
P2093
P2860
P1476
Tolerability and pharmacokinet ...... hildren's Oncology Group study
@en
P2093
Ashish M Ingle
Charlotte H Ahern
Joel M Reid
Julia Glade-Bender
Peter C Adamson
Steven G DuBois
Suzanne Shusterman
Sylvain Baruchel
P2860
P2888
P304
P356
10.1007/S00280-011-1798-2
P577
2011-12-18T00:00:00Z
P6179
1026843941